CL2021001073A1 - Análogos de proteína tirosina-tirosina y métodos de uso de esta - Google Patents

Análogos de proteína tirosina-tirosina y métodos de uso de esta

Info

Publication number
CL2021001073A1
CL2021001073A1 CL2021001073A CL2021001073A CL2021001073A1 CL 2021001073 A1 CL2021001073 A1 CL 2021001073A1 CL 2021001073 A CL2021001073 A CL 2021001073A CL 2021001073 A CL2021001073 A CL 2021001073A CL 2021001073 A1 CL2021001073 A1 CL 2021001073A1
Authority
CL
Chile
Prior art keywords
tyrosine
analogs
methods
pyy
protein
Prior art date
Application number
CL2021001073A
Other languages
English (en)
Inventor
Daniel Anthony Briere
Daniel Christopher Lopes
Avinash Muppidi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68582448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021001073A1 publication Critical patent/CL2021001073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen análogos de PYY que incluyen modificaciones que aumentan la semivida en comparación con PYY humano, nativo, así como modificaciones adicionales que aumentan la potencia y selectividad para el receptor NPY2. También se describen composiciones farmacéuticas que incluyen uno o más de los análogos de PYY descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se describen métodos para elaborar y usar los análogos de PYY, especialmente para tratar la obesidad y las enfermedades y los trastornos relacionados con la obesidad, tales como diabetes mellitus tipo II.
CL2021001073A 2018-11-01 2021-04-26 Análogos de proteína tirosina-tirosina y métodos de uso de esta CL2021001073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754244P 2018-11-01 2018-11-01
US201962793544P 2019-01-17 2019-01-17

Publications (1)

Publication Number Publication Date
CL2021001073A1 true CL2021001073A1 (es) 2021-11-12

Family

ID=68582448

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001073A CL2021001073A1 (es) 2018-11-01 2021-04-26 Análogos de proteína tirosina-tirosina y métodos de uso de esta

Country Status (23)

Country Link
US (4) US11155592B2 (es)
EP (1) EP3873924A1 (es)
JP (2) JP7280949B2 (es)
KR (3) KR20250153864A (es)
CN (2) CN112888705B (es)
AU (3) AU2019371232B2 (es)
BR (1) BR112021006782A2 (es)
CA (1) CA3118002A1 (es)
CL (1) CL2021001073A1 (es)
CO (1) CO2021005514A2 (es)
CR (1) CR20210192A (es)
DO (1) DOP2021000072A (es)
EC (1) ECSP21030933A (es)
IL (2) IL282177B2 (es)
JO (1) JOP20210089A1 (es)
MX (1) MX2021004930A (es)
MY (1) MY197530A (es)
PE (1) PE20211466A1 (es)
PH (1) PH12021550964A1 (es)
SA (1) SA521421873B1 (es)
SG (1) SG11202104161RA (es)
TW (3) TW202535916A (es)
WO (1) WO2020092191A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
IL297368A (en) * 2020-04-17 2022-12-01 I2O Therapeutics Inc Long-acting peptide tyrosine kinase (pyy) analogs and methods of use
JP7661478B2 (ja) * 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
CN114075265B (zh) * 2020-08-13 2025-08-29 珠海市丽珠微球科技有限公司 一种多肽酪氨酸酪氨酸类似物以及包含其的缓释制剂
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
JP2025526148A (ja) 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療
JP2025530743A (ja) 2022-08-29 2025-09-17 イーライ リリー アンド カンパニー 経口投与のための組成物
CN117603364A (zh) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
CN120958017A (zh) 2023-04-10 2025-11-14 联邦生物科技(珠海横琴)有限公司 酪酪肽类似物及其应用
TW202535961A (zh) * 2023-12-12 2025-09-16 美商卡默療法股份有限公司 具有經取代之色胺酸殘基或末端取代基的雜合肽化合物
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue
WO2025169190A2 (en) * 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases
WO2026073030A1 (en) * 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
EP1474163A2 (en) * 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US20070027073A1 (en) 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
WO2009138511A1 (en) 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
AU2014261111B2 (en) * 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
JP2023082013A (ja) 2023-06-13
AU2022231763A1 (en) 2022-10-06
AU2019371232B2 (en) 2022-07-14
US20240209055A1 (en) 2024-06-27
JP7280949B2 (ja) 2023-05-24
JP2022506070A (ja) 2022-01-17
CN112888705A (zh) 2021-06-01
MY197530A (en) 2023-06-21
KR102667979B1 (ko) 2024-05-24
PE20211466A1 (es) 2021-08-05
KR102869806B1 (ko) 2025-10-14
US20250230213A1 (en) 2025-07-17
TWI865836B (zh) 2024-12-11
WO2020092191A1 (en) 2020-05-07
EP3873924A1 (en) 2021-09-08
IL282177B1 (en) 2025-07-01
JOP20210089A1 (ar) 2019-10-28
AU2019371232A1 (en) 2021-05-20
SG11202104161RA (en) 2021-05-28
NZ775435A (en) 2025-02-28
CA3118002A1 (en) 2020-05-07
US11155592B2 (en) 2021-10-26
KR20250153864A (ko) 2025-10-27
DOP2021000072A (es) 2021-05-31
SA521421873B1 (ar) 2024-08-05
PH12021550964A1 (en) 2021-11-29
AU2024205661A1 (en) 2024-08-29
CN120058903A (zh) 2025-05-30
IL321547A (en) 2025-08-01
IL282177B2 (en) 2025-11-01
AU2022231763B2 (en) 2024-05-09
KR20210071038A (ko) 2021-06-15
TW202208410A (zh) 2022-03-01
US11820803B2 (en) 2023-11-21
TW202033544A (zh) 2020-09-16
KR20240093737A (ko) 2024-06-24
US12269857B2 (en) 2025-04-08
US20220025009A1 (en) 2022-01-27
CO2021005514A2 (es) 2021-05-10
CN112888705B (zh) 2025-03-11
ECSP21030933A (es) 2021-05-31
IL282177A (en) 2021-05-31
TWI749381B (zh) 2021-12-11
TW202535916A (zh) 2025-09-16
CR20210192A (es) 2021-05-18
MX2021004930A (es) 2021-06-08
US20200140514A1 (en) 2020-05-07
BR112021006782A2 (pt) 2021-07-13
JP7851877B2 (ja) 2026-04-27

Similar Documents

Publication Publication Date Title
CL2021001073A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
ECSP22007726A (es) Análogos de relaxina y métodos para usarlos
CO2020014180A2 (es) Derivados de gip y usos de estos
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
CL2019001265A1 (es) Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
PE20160683A1 (es) Analogos de glucagon acilados
PE20210162A1 (es) Analogos de incretina y sus usos
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CL2019003660A1 (es) Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2).
MX372841B (es) Análogo acilado del glucagón.
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
MX2021005822A (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr.
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2023006811A (es) Compuestos novedosos.
PH12021550839A1 (en) Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
AR114080A1 (es) Anticuerpos pac1 y sus usos
JOP20230150A1 (ar) صيغ ببتيد علاجية
AR116803A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
CO2022011101A2 (es) Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos
EA202190923A1 (ru) Аналоги белка тирозин-тирозин и способы их применения
AR119473A1 (es) Análogos de relaxina y métodos para usarlos
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина